Νευρολογία

NOVEL FUTURE THERAPEUTIC OPTIONS IN MYASTHENIA GRAVIS, ΜΕΡΟΣ Α’

ABSTRACT Myasthenia gravis (MG) is an autoimmune disease caused by complement-fixing antibodies against the acetylcholine receptors (AChR). Antigen-specific CD4+ T cells, Tregs and  Th17+ are also necessary. Accordingly, antibodies, B cells, molecules associated with signalling pathways on T helper cells, cytokines and complement are targets for future treatment options in MG. Novel biological agents directed…